Clinical Trials Browser

Phase 2 × Myelodysplastic Syndromes × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00488592 2021-07-12

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Phase 2 Completed

10 enrolled 7 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT01158118 2017-06-05

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

Phase 2 Completed

48 enrolled 17 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00533923 2016-07-18

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

Phase 2 Completed

25 enrolled

Classical hematologyLymphoidMyeloidPlasma cell

Anemia, Aplastic, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis

NCT01542684 2014-04-30

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

Phase 2 Terminated

8 enrolled 5 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

Clinical Trials

Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)